Primary care doctors in the UK are a “negligible” provider of commercial clinical trial activity and should be incentivised to give experimental therapies to patients.
It seems to be in our nature to think of things as binary: you prefer the beach over the mountains; you like sweet treats rather than salty; this is correct and that is wrong.
A survey of people in the UK has found that two thirds (69%) of them would consider taking part in a clinical trial, with a financial incentive the most compelling reason
CVS Health has decided to shut down its clinical trials business, just two years after launching it to great fanfare in the midst of the COVID-19 pandemic.
Despite the subtle change and lack of immediate impact on patients, the FDA Modernization Act 2.0 is anything but inconsequential, as Pepper Bio's Samantha Dale explains